Effects of galantamine on social interaction impairments in cholecystokinin receptor-2 overexpression mice

  • J Pharmacol Sci. 2022 Apr;148(4):364-368. doi: 10.1016/j.jphs.2022.02.006.
Shota Tanase  1 ,  Takayoshi Mamiya  2 ,  Shogo Nagata  1 ,  Yusuke Ikawa  1 ,  Ya-Ping Tang  3 ,  Masayuki Hiramatsu  4 ,  Toshitaka Nabeshima  5
Affiliations
  • 1. Department of Chemical Pharmacology, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
  • 2. Department of Chemical Pharmacology, Faculty of Pharmacy, Meijo University, Nagoya, Japan; Japanese Drug Organization of Appropriate Use and Research, Nagoya, Japan. Electronic address: [email protected].
  • 3. Joint Center of Translational Precision Medicine, Guangzhou Institute of Pediatrics, Guangzhou Women and Children Medical Center, Guangzhou, China.
  • 4. Department of Chemical Pharmacology, Faculty of Pharmacy, Meijo University, Nagoya, Japan; Japanese Drug Organization of Appropriate Use and Research, Nagoya, Japan.
  • 5. Japanese Drug Organization of Appropriate Use and Research, Nagoya, Japan; Advanced Diagnostic System Research Laboratory, Graduate School of Health Sciences, Fujita Health University, Toyoake, Japan.
PMID: 35300811 DOI: 10.1016/j.jphs.2022.02.006
Abstract

We examined whether galantamine (GAL), a cholinesterase inhibitor and allosteric potentiating ligand for α7 nicotinic acetylcholine receptor (nAChR), had an impact on emotional abnormalities in forebrain-specific cholecystokinin receptor-2 overexpressed transgenic mice. Treatment with GAL (1 mg/kg, s.c.) attenuated the decrease of social interaction time, but failed to attenuate anxiety-like behavior in the elevated plus-maze test. The effect of GAL was blocked by an α7 nAChR antagonist, methyllycaconitine (3 mg/kg, i.p.). These results suggest that GAL improved social interaction impairments via α7 nAChR and could be useful to treat sociability-related emotional abnormalities.

Keywords
Cholecystokinin receptor transgenic mice; Galantamine; Social interaction.
Products